Lilly drug shows nearly 21% weight loss in type 2 diabetes trial

Eli Lilly has reported that an experimental drug under investigation helped adults living with type 2 diabetes and obesity achieve substantial weight loss in a late-stage clinical trial.

According to the company, participants in the trial lost an average of nearly 21% of their body weight. The finding was announced on Tuesday.

The result comes from a late-stage study, the final phase of clinical testing before a treatment can be submitted for regulatory review. The trial enrolled adults who had both type 2 diabetes and obesity.

The company did not provide further details on the trial, including the number of participants, the duration of treatment or the specific name of the drug candidate.

Obesity and type 2 diabetes are closely linked conditions, and treatments that address both are of considerable interest to researchers and clinicians. The reported weight-loss figure, if confirmed, would place the drug among the more effective therapies currently in development for this patient group.

Further data from the trial are expected to be presented or published as the company moves through the regulatory process.